Changes of estrogen receptor, progesterone receptor and C-erbB-2 expressions in different scheme pre-and post-neoadjuvant chemotherapies for breast cancer
10.3760/cma.j.issn.1673-422X.2013.02.012
- VernacularTitle:乳腺癌雌激素受体、孕激素受体和C-erbB-2在不同新辅助化疗前后的变化
- Author:
Pengliang SHI
;
Naiqian ZHANG
;
Guoqiang ZHANG
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Neoadjuvant chemotherapy;
Receptors,estrogen;
Receptors,progesterone;
Receptor,erbB-2
- From:
Journal of International Oncology
2013;(2):117-119
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant chemotherapy is widely used in the therapy of locally advanced breast cancer.In the recent studies,the expressions of ER,PR and C-erbB-2 in tumor may change in different scheme preand post-neoadjuvant chemotherapies for breast cancer.It is obviously changed in the neoadjuvant chemotherapy scheme of anthracyclines and paclitaxel/docetaxel,but hardly changed in anthracycline-based neoadjuvant chemotherapy scheme.
